ANI Pharmaceuticals (ANIP) Scheduled to Post Earnings on Friday

ANI Pharmaceuticals (NASDAQ:ANIP) is scheduled to be posting its quarterly earnings results before the market opens on Friday, May 10th. Analysts expect ANI Pharmaceuticals to post earnings of $0.98 per share for the quarter. ANI Pharmaceuticals has set its FY24 guidance at $4.26-4.67 EPS and its FY 2024 guidance at 4.260-4.670 EPS.Parties interested in listening to the company’s conference call can do so using this link.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Thursday, February 29th. The specialty pharmaceutical company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. ANI Pharmaceuticals had a net margin of 3.86% and a return on equity of 18.06%. The firm had revenue of $131.65 million for the quarter, compared to analyst estimates of $123.02 million. On average, analysts expect ANI Pharmaceuticals to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

ANI Pharmaceuticals Stock Down 1.0 %

Shares of ANIP stock opened at $66.72 on Wednesday. ANI Pharmaceuticals has a 12-month low of $38.91 and a 12-month high of $70.81. The company has a quick ratio of 2.81, a current ratio of 3.57 and a debt-to-equity ratio of 0.66. The firm has a fifty day moving average of $66.86 and a 200-day moving average of $59.32. The company has a market capitalization of $1.41 billion, a price-to-earnings ratio of 79.43 and a beta of 0.80.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Capital One Financial began coverage on ANI Pharmaceuticals in a report on Friday, March 15th. They set an “overweight” rating and a $80.00 target price for the company. Guggenheim reiterated a “buy” rating and set a $77.00 price objective on shares of ANI Pharmaceuticals in a report on Tuesday, April 23rd. HC Wainwright boosted their target price on ANI Pharmaceuticals from $73.00 to $83.00 and gave the company a “buy” rating in a research note on Monday, March 4th. Finally, Truist Financial raised their price target on shares of ANI Pharmaceuticals from $72.00 to $80.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $80.00.

Insider Activity at ANI Pharmaceuticals

In other news, SVP Chad Gassert sold 20,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $66.62, for a total transaction of $1,332,400.00. Following the sale, the senior vice president now owns 233,226 shares in the company, valued at approximately $15,537,516.12. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other ANI Pharmaceuticals news, SVP Chad Gassert sold 20,000 shares of the stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $66.62, for a total value of $1,332,400.00. Following the completion of the sale, the senior vice president now owns 233,226 shares in the company, valued at $15,537,516.12. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Stephen P. Carey sold 7,787 shares of the business’s stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $65.55, for a total transaction of $510,437.85. Following the transaction, the chief financial officer now owns 177,712 shares in the company, valued at $11,649,021.60. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 176,803 shares of company stock valued at $11,695,866. 12.70% of the stock is owned by insiders.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.